Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
84.68 EUR | +1.41% |
|
+0.55% | -0.02% |
02-07 | Henkel: sale of private labels in America | CF |
02-07 | Handles rise and test resistance | DP |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 20.11B | 19.25B | 20.07B | 22.4B | 21.51B | |||||
Total Revenues | 20.11B | 19.25B | 20.07B | 22.4B | 21.51B | |||||
Cost of Goods Sold, Total | 10.81B | 10.26B | 11B | 12.92B | 11.67B | |||||
Gross Profit | 9.3B | 8.99B | 9.07B | 9.47B | 9.84B | |||||
Selling General & Admin Expenses, Total | 5.69B | 6.22B | 6.03B | 6.82B | 6.79B | |||||
R&D Expenses | 487M | 494M | 504M | 544M | 581M | |||||
Other Operating Expenses | -63M | 37M | -43M | -46M | -212M | |||||
Other Operating Expenses, Total | 6.12B | 6.75B | 6.49B | 7.32B | 7.16B | |||||
Operating Income | 3.18B | 2.24B | 2.57B | 2.16B | 2.68B | |||||
Interest Expense, Total | -88M | -55M | -46M | -73M | -106M | |||||
Interest And Investment Income | 13M | 12M | 28M | 37M | 73M | |||||
Net Interest Expenses | -75M | -43M | -18M | -36M | -33M | |||||
Currency Exchange Gains (Loss) | 4M | -33M | -20M | -31M | -17M | |||||
Other Non Operating Income (Expenses) | -13M | -12M | -23M | -49M | -66M | |||||
EBT, Excl. Unusual Items | 3.1B | 2.15B | 2.51B | 2.04B | 2.56B | |||||
Restructuring Charges | -294M | -237M | -228M | -404M | -267M | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Impairment of Goodwill | - | -31M | - | -88M | -1M | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Assets | 10M | 15M | 46M | 46M | -415M | |||||
Asset Writedown | -27M | - | -208M | 88M | 2M | |||||
Insurance Settlements | 13M | 13M | 17M | 7M | 5M | |||||
Legal Settlements | - | - | - | - | - | |||||
Other Unusual Items | 8M | 16M | 8M | - | - | |||||
EBT, Incl. Unusual Items | 2.81B | 1.92B | 2.15B | 1.69B | 1.89B | |||||
Income Tax Expense | 708M | 501M | 519M | 436M | 549M | |||||
Earnings From Continuing Operations | 2.1B | 1.42B | 1.63B | 1.25B | 1.34B | |||||
Net Income to Company | 2.1B | 1.42B | 1.63B | 1.25B | 1.34B | |||||
Minority Interest | -18M | -16M | 5M | 5M | -22M | |||||
Net Income - (IS) | 2.08B | 1.41B | 1.63B | 1.26B | 1.32B | |||||
Net Income to Common Incl Extra Items | 2.08B | 1.41B | 1.63B | 1.26B | 1.32B | |||||
Net Income to Common Excl. Extra Items | 2.08B | 1.41B | 1.63B | 1.26B | 1.32B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 4.8 | 3.24 | 3.76 | 2.94 | 3.14 | |||||
Basic EPS - Continuing Operations | 4.8 | 3.24 | 3.76 | 2.94 | 3.14 | |||||
Basic Weighted Average Shares Outstanding | 434M | 434M | 434M | 428M | 420M | |||||
Net EPS - Diluted | 4.8 | 3.24 | 3.76 | 2.94 | 3.14 | |||||
Diluted EPS - Continuing Operations | 4.8 | 3.24 | 3.76 | 2.94 | 3.14 | |||||
Diluted Weighted Average Shares Outstanding | 434M | 434M | 434M | 428M | 420M | |||||
Normalized Basic EPS | 4.42 | 3.06 | 3.63 | 2.99 | 3.77 | |||||
Normalized Diluted EPS | 4.42 | 3.06 | 3.63 | 2.99 | 3.77 | |||||
Dividend Per Share | 1.85 | 1.85 | 1.85 | 1.85 | 1.85 | |||||
Payout Ratio | 38.27 | 56.68 | 48.84 | 63.15 | 58.5 | |||||
American Depositary Receipts Ratio (ADR) | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | |||||
Supplemental Items | ||||||||||
EBITDA | 3.72B | 2.76B | 3.09B | 2.69B | 3.18B | |||||
EBITA | 3.29B | 2.34B | 2.66B | 2.24B | 2.75B | |||||
EBIT | 3.18B | 2.24B | 2.57B | 2.16B | 2.68B | |||||
EBITDAR | 3.76B | 2.79B | 3.11B | 2.71B | 3.2B | |||||
Effective Tax Rate - (Ratio) | 25.19 | 26.03 | 24.16 | 25.8 | 29.06 | |||||
Total Current Taxes | 644M | 686M | 759M | 505M | 520M | |||||
Total Deferred Taxes | 64M | -185M | -239M | -69M | 29M | |||||
Normalized Net Income | 1.92B | 1.33B | 1.58B | 1.28B | 1.58B | |||||
Interest on Long-Term Debt | 16M | 16M | 14M | 18M | 21M | |||||
Non-Cash Pension Expense | 2M | -5M | 0 | -2M | 4M | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 4.8B | 5.3B | 5.1B | 5.78B | 5.72B | |||||
General and Administrative Expenses | 892M | 913M | 928M | 1.03B | 1.07B | |||||
Research And Development Expense From Footnotes | 499M | 501M | 727M | 570M | 587M | |||||
Net Rental Expense, Total | 41M | 24M | 23M | 20M | 15M | |||||
Imputed Operating Lease Interest Expense | 6.65M | 2.59M | 2.39M | 3.32M | 3.91M | |||||
Imputed Operating Lease Depreciation | 34.35M | 21.41M | 20.61M | 16.68M | 11.09M | |||||
Stock-Based Comp., Other (Total) | 11M | 28M | 30M | 34M | 27M | |||||
Total Stock-Based Compensation | 11M | 28M | 30M | 34M | 27M |